Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesDividends payablesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oramed Pharmaceuticals (ORMP) Receivables (2016 - 2018)

Oramed Pharmaceuticals filings provide 8 years of Receivables readings, the most recent being $65000.0 for Q1 2018.

  • Quarterly Receivables changed N/A to $65000.0 in Q1 2018 from the year-ago period, while the trailing twelve-month figure was $65000.0 through Feb 2018, changed N/A year-over-year, with the annual reading at $65000.0 for FY2017, 0.0% changed from the prior year.
  • Receivables hit $65000.0 in Q1 2018 for Oramed Pharmaceuticals, roughly flat from $65000.0 in the prior quarter.
  • Across five years, Receivables topped out at $395000.0 in Q3 2014 and bottomed at $65000.0 in Q3 2015.
  • Average Receivables over 5 years is $113819.1, with a median of $65000.0 recorded in 2015.
  • The largest annual shift saw Receivables surged 41.42% in 2014 before it tumbled 83.54% in 2015.
  • Oramed Pharmaceuticals' Receivables stood at $92000.0 in 2014, then dropped by 29.35% to $65000.0 in 2015, then changed by 0.0% to $65000.0 in 2016, then changed by 0.0% to $65000.0 in 2017, then changed by 0.0% to $65000.0 in 2018.
  • Per Business Quant, the three most recent readings for ORMP's Receivables are $65000.0 (Q1 2018), $65000.0 (Q4 2017), and $65000.0 (Q3 2017).